annual meeting program - American Society of Clinical Oncology

MONDAY
Monday, June 7, 2010
Brd. 43B An evaluation of health literacy (HL) in a consecutive sample of patients (pts)
with cancer (ca) of the head and neck (H�N) region. (Abstract #9069)
K. Koay, P. Schofield, K. Gough, R. Buchbinder, D. Rischin, J. Corry, M. Jefford
Brd. 43C Innovative quality initiative measurement using Web-based drug dispensing
technology with interactive physician queries to evaluate bisphosphonate
use across community oncology practices nationwide. (Abstract #9070)
C. G. Baker, G. Grabavoy, I. Aksamit, H. J. McKenzie, K. A. Bergstrom
Brd. 43D The associations between spirituality (S), religiosity (R), and spiritual pain
(SP) in advanced cancer patients (AdCa). (Abstract #9071)
M. O. Delgado-Guay, D. Hui, H. A. Parsons, M. De la Cruz, K. B. Govan,
L. Arciniega, S. Thorney, J. L. Palmer, E. Bruera
Brd. 43E The effect of cytotoxic chemotherapy on the risk of high-grade acneiform
rash with cetuximab in cancer patients: A meta-analysis. (Abstract #9072)
Y. Balagula, S. Wu, X. Su, S. W. Dusza, M. E. Lacouture
Brd. 43F Use of unnecessary medications by terminally ill cancer patients.
(Abstract #9073)
R. Riechelmann, A. B. Fede, M. C. Miranda, D. V. Antonangelo,
H. L. Schaffhausser, L. Trevizan, B. Hamermesz, C. Zimmermann, A. Del Giglio
Brd. 43G Polypharmacy in elderly cancer patients. (Abstract #9074)
T. L. Jorgensen, J. Hallas, J. Herrstedt
Brd. 43H The association between clinical, sociodemographic, and
logistic-administrative factors and adherence to completing health-related
quality-of-life questionnaires. (Abstract #9075)
J. Vercauteren, J. Maringwa, C. Coens, C. Quinten, C. Gotay, J. Ringash, M. King,
D. Osoba, H. Flechtner, A. Bottomley, on behalf of the EORTC
Brd. 44A Evaluation of variants of the rs1934951 locus of CYP2C8 and
bisphosphonate-related osteonecrosis of the jaw in castrate-resistant
prostate cancer (CRPC) patients. (Abstract #9076)
P. G. Kluetz, B. C. English, C. E. Baum, T. M. Sissung, D. Adelberg, W. L. Dahut,
D. K. Price, W. D. Figg
Brd. 44B An exploratory analysis of transfusion risk when initiating darbepoetin alfa
(DA) therapy at baseline hemoglobin (Hb) < 9 g/dl vs 9 to < 10 g/dl versus
>10 g/dl in patients (pts) with chemotherapy-induced anemia (CIA).
(Abstract #9077)
J. R. Canon, J. F. Vansteenkiste, M. Hedenus, P. Gascon, C. Bokemeyer,
H. Ludwig, J. B. Vermorken, J. C. Legg, K. R. Bridges, B. Pujol
Brd. 44C Interpretation of do-not-resuscitate (DNR) orders among oncology health
care professionals and the potential for these orders to influence care for
medical issues unrelated to resuscitation. (Abstract #9078)
C. R. Lund, R. Samant
Brd. 44D How accurate is clinician reporting of chemotherapy side effects? A
prospective study comparing clinician with patient-reported symptoms.
(Abstract #9079)
S. Ghosh, M. Van Hemelrijck, C. D. Holdridge, J. F. Gibson, P. J. Ross, J. Mansi,
R. Lal, P. A. Ellis, P. G. Harper, S. Chowdhury
Brd. 44E The effect of palliative care consultations on the end-of-life care in the
Veteran’s cancer population. (Abstract #9080)
W. Gonsalves, T. Tashi, I. Aldoss, M. Kalaiah, N. Didwaniya, S. Stenoien,
C. Eberle, A. Ganti, S. Subbiah, P. T. Silberstein
Brd. 44F Validation of first speech-specific questionnaire for English-speaking head
and neck cancer (HNC) patients. (Abstract #9081)
R. Kazi, R. C. Dwivedi, S. St. Rose, J. W. Roe, C. Nutting, P. H. Rhys-Evans,
K. J. Harrington
Brd. 44G Differences in lung cancer clinical trial accrual between a public and
university medical oncology clinic. (Abstract #9082)
S. j. Vara, D. E. Gerber, A. Avila, J. Bolluyt, J. Yan, Y. Xie, J. H. Schiller
380